Clinical Trials A continuación, se enumeran los ensayos clínicos actuales.386 estudios en Cancer (solo estudios abiertos). Filtra esta lista de estudios por sede, estado, etc. Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT) Jacksonville, Fla. UP-NEXT is a double-blind, randomized, placebo controlled study of the antibody-drug conjugate (ADC) XMT-1536 (upifitamab rilsodotin) administered as an intravenous infusion for patients once every four weeks. Patients with recurrent, platinum-sensitive high-grade serous ovarian cancer (HGSOC) including fallopian tube and primary peritoneal cancer expressing high levels of NaPi2b. A Study of the Health Issues of Bleeding Disorders Rochester, Minn. The purpose of this study is to monitor and better understand the health issues of people with bleeding disorders. A Registry Study for the Long-Term Outcomes of Radiation Therapy Scottsdale/Phoenix, Ariz. The purpose of this long term registry study is to collect and analyze information from patients being treated with various forms of radiation therapy to improve the treatment of future patients. A Study to Collect Medical and Personal Histories, Blood and/or Tumor Tissue Samples from Patients Who are Long-term Survivors of Lung Cancer Rochester, Minn. The purpose of this study is to collect medical and personal histories, blood and/or tumor tissue samples from patients who are long-term survivors of lung cancer. This study will help us to develop better ways to provide care and advice, develop better treatments to minimize long-term side effects, and improve the quality of life and outcome of lung cancer patients. This study will also help us to learn whether certain genes (inherited factors from your parents) increase the risk of developing or dying of lung cancer. (Apex) CGT9486 in Patients With Advanced Systemic Mastocytosis Scottsdale/Phoenix, Ariz. The purpose of this study is to investigate CGT9486 for the treatment of patients with Advanced Systemic Mastocytosis (AdvSM), including patients with Aggressive SM. (ASM), System Mastocytosis (SM) with Associated Hematologic Neoplasm (SM-AHN), and Mast Cell Leukemia (MCL). Blood-Brain Barrier Disruption (BBBD) for Liquid Biopsy in Subjects With GlioBlastoma Brain Tumors Rochester, Minn. The purpose of this study is to evaluate the safety and effectiveness of using Exablate Model 4000 Type-2.0/2.1 in adults with Glioblastoma brain tumors to increase temporarily the permeability of the blood brain barrier, allowing increased passage of circulating free DNA (cfDNA) for sampling and analysis. Melanoma In-transit Tissue Bank and Molecular Analysis for Personalized Therapies Rochester, Minn., Jacksonville, Fla. The purpose of this study is to establish a tissue bank to collect patient tissue for genomic analysis, allowing identification of genomic signatures that predict response and failure to the individual therapy. Once this is complete treatment will be directed based on the genomic signature of patients individual tumor. Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer Jacksonville, Fla. The purpose of this study is to compare the effect of adding durvalumab to chemotherapy versus chemotherapy alone before surgery in treating patients with upper urinary tract cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as methotrexate, vinblastine, doxorubicin, cisplatin, and gemcitabine work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Durvalumab in combination with chemotherapy before surgery may enhance the shrinking of the tumor compared to chemotherapy alone. A Study to Evaluate RP1 Monotherapy and Combined with Nivolumab Rochester, Minn., Scottsdale/Phoenix, Ariz. The purpose of this study is to evaluate the dose escalation and expansion of RP1 alone and combined with nivolumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary effectiveness. Evaluating Intestinal Microbiome and Immune Function in Lymphoma Rochester, Minn. The purpose of this study is to examine the microbiome and immune function in patients with active lymphoma, and in patients with a history of lymphoma who are in clinical remission. Numeración de páginas Estudios clínicos AnteriorPágina anterior Ir a página 2626 Ir a página 2727 Ir a página 2828 Ir a página 2929 Ir a página 3030 SiguientePróxima página Profesionales médicos Cancer clinical-trials